Ingmar Blümcke1,2, Roland Coras1, Robyn M Busch2,3,4, Marcia Morita-Sherman2, Dennis Lal2,4, Richard Prayson5, Fernando Cendes6,7, Iscia Lopes-Cendes7,8, Fabio Rogerio7,9, Vanessa S Almeida7,8, Cristiane S Rocha7,8, Nam Suk Sim10, Jeong Ho Lee10,11, Se Hoon Kim12, Stephanie Baulac13, Sara Baldassari13, Homa Adle-Biassette14,15, Christopher A Walsh16,17, Sara Bizzotto16,17, Ryan N Doan16,17, Katherine S Morillo16,17, Eleonora Aronica18,19, Angelika Mühlebner18,20, Albert Becker21, Jesus Cienfuegos22,23, Rita Garbelli24, Caterina Giannini25,26, Mrinalini Honavar27, Thomas S Jacques28,29, Maria Thom30, Anita Mahadevan31, Hajime Miyata32, Pitt Niehusmann33, Harvey B Sarnat34,35,36, Figen Söylemezoglu37, Imad Najm2,3. 1. Department of Neuropathology, University Hospital, Erlangen, Germany. 2. Epilepsy Center, Cleveland Clinic, Cleveland, OH, USA. 3. Department of Neurology, Cleveland Clinic, Cleveland, OH, USA. 4. Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, USA. 5. Department of Anatomic Pathology, Cleveland Clinic, Cleveland, OH, USA. 6. Department of Neurology, University of Campinas, Sao Paulo, Brazil. 7. Brazilian Institute of Neuroscience and Neurotechnology, Sao Paulo, Brazil. 8. Department of Medical Genetics and Genomic Medicine, University of Campinas, Sao Paulo, Brazil. 9. Department of Pathology, University of Campinas, Sao Paulo, Brazil. 10. Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, South Korea. 11. SoVarGen, Inc., Daejeon, Korea. 12. Department of Pathology, College of Medicine, Yonsei University, Seoul, South Korea. 13. Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Paris, France. 14. Pathological Anatomy Service, Public Hospital Network of Paris, Paris, France. 15. NeuroDiderot, Inserm U1141, University of Paris, Paris, France. 16. Division of Genetics and Genomics, Manton Center for Orphan Disease Research, Department of Pediatrics, and Howard Hughes Medical Institute, Boston Children's Hospital, Boston, MA, USA. 17. Departments of Pediatrics and Neurology, Harvard Medical School, Boston, MA, USA. 18. Department of (Neuro)Pathology, Amsterdam UMC, location Academic Medical Center, Amsterdam, the Netherlands. 19. Epilepsy Institutes of the Netherlands Foundation, Heemstede, the Netherlands. 20. Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands. 21. Department of Neuropathology, University of Bonn Medical Center, Bonn, Germany. 22. Department of Anatomic Pathology, International Center for Epilepsy Surgery, Humanitas Medical Group Hospital, Mexico City, Mexico. 23. Department of Anatomic Pathology, Angels Mexico Hospital, Mexico City, Mexico. 24. Epilepsy Unit, Carlo Besta Neurological Institute, Scientific Institute for Research and Health Care Foundation, Milan, Italy. 25. Anatomic Pathology, Mayo Clinic, Rochester, Minnesota, USA. 26. Department of Biomedical and Neuromotor Science,, Alma Mater Studiorum, University of Bologna, Bologna, Italy. 27. Department of Anatomic Pathology, Pedro Hispano Hospital, Matosinhos, Portugal. 28. Developmental Biology and Cancer Research and Teaching Programme, University College London Great Ormond Street Institute of Child Health, London, UK. 29. Department of Histopathology, Great Ormond Street Hospital for Children, National Health Service Foundation Trust, London, UK. 30. Department of Neuropathology, Institute of Neurology, University College London, London, UK. 31. Department of Neuropathology, National Institute of Mental Health and Neurosciences, Bangalore, India. 32. Department of Neuropathology, Research Institute for Brain and Blood Vessels, Akita Cerebrospinal and Cardiovascular Center, Akita, Japan. 33. Department of Neuro-/Pathology, Translational Neurodegeneration Research and Neuropathology Lab, University of Oslo and Oslo University Hospital, Oslo, Norway. 34. Department of Paediatrics, University of Calgary Faculty of Medicine, Alberta Children's Hospital Research Institute, Calgary, AB, Canada. 35. Department of Pathology (Neuropathology),, University of Calgary Faculty of Medicine, Alberta Children's Hospital Research Institute, Calgary, AB, Canada. 36. Department of Clinical Neurosciences, University of Calgary Faculty of Medicine, Alberta Children's Hospital Research Institute, Calgary, AB, Canada. 37. Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Abstract
OBJECTIVE: Focal cortical dysplasia (FCD) is a major cause of difficult-to-treat epilepsy in children and young adults, and the diagnosis is currently based on microscopic review of surgical brain tissue using the International League Against Epilepsy classification scheme of 2011. We developed an iterative histopathological agreement trial with genetic testing to identify areas of diagnostic challenges in this widely used classification scheme. METHODS: Four web-based digital pathology trials were completed by 20 neuropathologists from 15 countries using a consecutive series of 196 surgical tissue blocks obtained from 22 epilepsy patients at a single center. Five independent genetic laboratories performed screening or validation sequencing of FCD-relevant genes in paired brain and blood samples from the same 22 epilepsy patients. RESULTS: Histopathology agreement based solely on hematoxylin and eosin stainings was low in Round 1, and gradually increased by adding a panel of immunostainings in Round 2 and the Delphi consensus method in Round 3. Interobserver agreement was good in Round 4 (kappa = .65), when the results of genetic tests were disclosed, namely, MTOR, AKT3, and SLC35A2 brain somatic mutations in five cases and germline mutations in DEPDC5 and NPRL3 in two cases. SIGNIFICANCE: The diagnoses of FCD 1 and 3 subtypes remained most challenging and were often difficult to differentiate from a normal homotypic or heterotypic cortical architecture. Immunohistochemistry was helpful, however, to confirm the diagnosis of FCD or no lesion. We observed a genotype-phenotype association for brain somatic mutations in SLC35A2 in two cases with mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy. Our results suggest that the current FCD classification should recognize a panel of immunohistochemical stainings for a better histopathological workup and definition of FCD subtypes. We also propose adding the level of genetic findings to obtain a comprehensive, reliable, and integrative genotype-phenotype diagnosis in the near future.
OBJECTIVE:Focal cortical dysplasia (FCD) is a major cause of difficult-to-treat epilepsy in children and young adults, and the diagnosis is currently based on microscopic review of surgical brain tissue using the International League Against Epilepsy classification scheme of 2011. We developed an iterative histopathological agreement trial with genetic testing to identify areas of diagnostic challenges in this widely used classification scheme. METHODS: Four web-based digital pathology trials were completed by 20 neuropathologists from 15 countries using a consecutive series of 196 surgical tissue blocks obtained from 22 epilepsypatients at a single center. Five independent genetic laboratories performed screening or validation sequencing of FCD-relevant genes in paired brain and blood samples from the same 22 epilepsypatients. RESULTS: Histopathology agreement based solely on hematoxylin and eosin stainings was low in Round 1, and gradually increased by adding a panel of immunostainings in Round 2 and the Delphi consensus method in Round 3. Interobserver agreement was good in Round 4 (kappa = .65), when the results of genetic tests were disclosed, namely, MTOR, AKT3, and SLC35A2 brain somatic mutations in five cases and germline mutations in DEPDC5 and NPRL3 in two cases. SIGNIFICANCE: The diagnoses of FCD 1 and 3 subtypes remained most challenging and were often difficult to differentiate from a normal homotypic or heterotypic cortical architecture. Immunohistochemistry was helpful, however, to confirm the diagnosis of FCD or no lesion. We observed a genotype-phenotype association for brain somatic mutations in SLC35A2 in two cases with mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy. Our results suggest that the current FCD classification should recognize a panel of immunohistochemical stainings for a better histopathological workup and definition of FCD subtypes. We also propose adding the level of genetic findings to obtain a comprehensive, reliable, and integrative genotype-phenotype diagnosis in the near future.
Authors: Karen M J Van Loo; Gemma L Carvill; Albert J Becker; Karen Conboy; Alica M Goldman; Katja Kobow; Iscia Lopes-Cendes; Christopher A Reid; Erwin A van Vliet; David C Henshall Journal: Nat Rev Neurol Date: 2022-07-20 Impact factor: 44.711
Authors: Sonia Mayo; Irene Gómez-Manjón; Francisco Javier Fernández-Martínez; Ana Camacho; Francisco Martínez; Julián Benito-León Journal: Int J Mol Sci Date: 2022-04-28 Impact factor: 6.208
Authors: Shavonne L Massey; Hannah C Glass; Renée A Shellhaas; Sonia Bonifacio; Taeun Chang; Catherine Chu; Maria Roberta Cilio; Monica E Lemmon; Charles E McCulloch; Janet S Soul; Cameron Thomas; Courtney J Wusthoff; Rui Xiao; Nicholas S Abend Journal: J Pediatr Date: 2021-10-30 Impact factor: 4.406